ARVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
ARVINAS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$7.26+0.29 (+4.16%)
Close on Oct 19, 2026
- Market cap
- $476.98M
- P/E (TTM)
- 45.4
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2016 to 2025
Operating margin
-45.1%+421.3 pts over 5 years
Net margin
-30.8%+429.8 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | -0.3% | +26.0% | +58.9% | – |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | -27.5% | -16.2% | |
| Return on assets | – | -23.4% | -8.9% | |
| Current ratio | – | 14.29 | 4.92 | |
| Debt to equity | – | 0.00 | 0.00 | |
| Net debt to EBITDA | – | 4.99× | 1.23× | |
| Interest coverage | – | -1208.0× | – | |
| Capex to revenue | – | 24.7% | 0.7% | |
| Diluted shares | – | 40M | 71M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Arvinas generated $1.71B from operations and spent $110.00M on capital expenditure, dividends and share buybacks. 16% of that went back into the business.
Generated
$1.71B
Used
$110.00M
Capital expenditure$18.10M16%Dividends$00%Share buybacks$91.90M84%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-30.8%
×Asset turnover0.29×
×Equity multiplier1.82×
=Return on equity, FY2025-16.2%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -30.8% | 0.29× | 1.82× | -16.2% |
| FY2024 | -75.5% | 0.22× | 1.96× | -32.6% |
| FY2023 | -467.9% | 0.06× | 2.10× | -60.0% |
| FY2022 | -215.0% | 0.09× | 2.12× | -42.0% |
| FY2021 | -356.3% | 0.05× | 1.61× | -26.8% |
| FY2020 | -460.6% | 0.05× | 1.17× | -27.5% |
| FY2019 | -163.5% | 0.17× | 1.38× | -38.7% |
| FY2018 | -289.6% | 0.11× | 3.53× | -110.1% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
4of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$80.80M
- Cash generatingOperating cash flow above zero-$273.80M
- Return on assets improvedROA up on the prior year-15.2% → -7.4%
- Earnings backed by cashOperating cash flow above net income-$273.80M vs -$80.80M
- Less leverageLong-term debt to assets fell0.1% → 0.1%
- Better liquidityCurrent ratio rose4.64 → 4.92
- No dilutionShare count did not rise72M → 71M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.20 → 0.24